Journal of Clinical and Cellular Immunology
Open Access

Abstract

Successful Treatment of Follicular Non-Hodgkin’s Lymphoma with an offlabel Use of Lenalidomide: A Case Report

Maurizio Capuozzo, Alessandro Ottaiano, Eduardo Nava, Stefania Cascone, Adriano Vercellone, Principia Marotta, Claudia Cinque, Roberta Marra and Rosario V. Iaffaioli

Lenalidomide is an immunomodulatory agent, with anti-angiogenic and anti-neoplastic properties, which has been approved for multiple myeloma and for deletion 5q myelodysplastic syndromes. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma (FL), diffuse large B-cell lymphoma and transformed large cell lymphoma. This report describes a patient with relapsed/refractoryadvanced-stage follicular non-Hodgkin’s lymphoma (fNHL) treated with lenalidomide oral monotherapy. The patient refractory to 2 lines of chemotherapy was treated subsequently with an off-label use oflenalidomide 25 mg tablets. After 6 months follow-up, the patient has no detectable disease. The treatment was well tolerated and led to the complete regression of an aggressive variant of the disease.